Copy to clipboard 
Enovis reported 1Q25 orthopedic sales of $300.6 million, up 10.7% compared to the first quarter of 2024.
The company has generated momentum and excitement through new product introductions like the augmented reverse glenoid system in shoulders, the nebula stem and surgical impactor in hip and the next generation of ARVIS navigation.
Enovis said the overall orthopedic market had a strong start in January and February, but slowed in March due to vacations and trade shows. The company sees the U.S. market as normalized, but international markets retaining some elevated demand.
“Practically speaking, [international] markets are probably a little stronger than they might be over time,” said Enovis CEO Matt Trerotola. “As the markets continue to normalize, we are going to be driving more cross-selling and expand our delta to the markets. We certainly believe that international can play the role they need to play in our overall Recon strategic growth.”
For 2025, Enovis expects its Recon business to grow in the high single digits on an organic basis.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $249.9 | $223.8 | $26.1 | 11.7% |
| Knees | $58.7 | $51.5 | $7.2 | 14.1% |
| Hips | $83.0 | $74.6 | $8.4 | 11.3% |
| Extremities | $108.2 | $97.8 | $10.4 | 10.7% |
| Trauma | $27.8 | $25.7 | $2.0 | 7.9% |
| Other | $22.9 | $22.0 | $0.9 | 4.3% |
| Total | $300.6 | $271.5 | $29.1 | 10.7% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $144.8 | $130.6 | $14.2 | 10.9% |
| OUS | $155.8 | $140.9 | $14.9 | 10.6% |
| EMEA | $124.0 | $111.3 | $12.7 | 11.4% |
| APAC | $20.3 | $19.0 | $1.3 | 6.8% |
| ROW | $11.5 | $10.6 | $0.9 | 8.8% |
| Total | $300.6 | $271.5 | $29.1 | 10.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $516.3 | |
| Cost of Sales | $218.4 | 42.3% |
| Selling and Admin | $255.7 | 49.5% |
| R&D | $23.4 | 10.7% |
| Other | $90.8 | 17.6% |
| Net Earnings | ($72.0) | (13.9%) |
Enovis reported 1Q25 orthopedic sales of $300.6 million, up 10.7% compared to the first quarter of 2024.
The company has generated momentum and excitement through new product introductions like the augmented reverse glenoid system in shoulders, the nebula stem and surgical impactor in hip and the next generation of ARVIS navigation.
...
Enovis reported 1Q25 orthopedic sales of $300.6 million, up 10.7% compared to the first quarter of 2024.
The company has generated momentum and excitement through new product introductions like the augmented reverse glenoid system in shoulders, the nebula stem and surgical impactor in hip and the next generation of ARVIS navigation.
Enovis said the overall orthopedic market had a strong start in January and February, but slowed in March due to vacations and trade shows. The company sees the U.S. market as normalized, but international markets retaining some elevated demand.
“Practically speaking, [international] markets are probably a little stronger than they might be over time,” said Enovis CEO Matt Trerotola. “As the markets continue to normalize, we are going to be driving more cross-selling and expand our delta to the markets. We certainly believe that international can play the role they need to play in our overall Recon strategic growth.”
For 2025, Enovis expects its Recon business to grow in the high single digits on an organic basis.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $249.9 | $223.8 | $26.1 | 11.7% |
| Knees | $58.7 | $51.5 | $7.2 | 14.1% |
| Hips | $83.0 | $74.6 | $8.4 | 11.3% |
| Extremities | $108.2 | $97.8 | $10.4 | 10.7% |
| Trauma | $27.8 | $25.7 | $2.0 | 7.9% |
| Other | $22.9 | $22.0 | $0.9 | 4.3% |
| Total | $300.6 | $271.5 | $29.1 | 10.7% |
Orthopedic Sales by Geography
| Region | 1Q25 | 1Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $144.8 | $130.6 | $14.2 | 10.9% |
| OUS | $155.8 | $140.9 | $14.9 | 10.6% |
| EMEA | $124.0 | $111.3 | $12.7 | 11.4% |
| APAC | $20.3 | $19.0 | $1.3 | 6.8% |
| ROW | $11.5 | $10.6 | $0.9 | 8.8% |
| Total | $300.6 | $271.5 | $29.1 | 10.7% |
Company Earnings
| Amt | % of Sales | |
|---|---|---|
| Sales | $516.3 | |
| Cost of Sales | $218.4 | 42.3% |
| Selling and Admin | $255.7 | 49.5% |
| R&D | $23.4 | 10.7% |
| Other | $90.8 | 17.6% |
| Net Earnings | ($72.0) | (13.9%) |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
